This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deichmann, M. Articles by Näher, H. Search for Related Content PubMed PubMed Citation Articles by Deichmann, M. Articles by Näher, H. Social Bookmarking                            What's this?

S100-Beta, Melanoma-Inhibiting Activity, and Lactate Dehydrogenase Discriminate Progressive From Nonprogressive American Joint Committee on Cancer Stage IV Melanoma

From the Department of Dermatology, University of Heidelberg, and Central Unit of Biostatistics R0700, German Cancer Research Center, Heidelberg, Germany.

Address reprint requests to Martin Deichmann, MD, Department of Dermatology, University of Heidelberg, Voßstraße 2, 69115 Heidelberg, Germany.

PURPOSE: Monitoring advanced malignant melanoma, serum levels of S100-beta (S100ß) and melanoma-inhibiting activity (MIA) were assessed for the ability to discriminate progressive from nonprogressive disease. S100ß and MIA were supposed to be superior to conventional variables, such as lactate dehydrogenase (LDH) level.

PATIENTS AND METHODS: Seventy-one patients with stage IV malignant melanoma according to the criteria of the American Joint Committee on Cancer (AJCC) were included in the study. Results of restaging examinations were used as an independent reference standard for diagnosing progressive disease, and S100ß, MIA, LDH level, and erythrocyte sedimentation rate (ESR) were determined in venous blood just before restaging. Sensitivities and specificities of the parameters were calculated by logistic regression analysis. Discrimination ability was assessed by Somers' D_xy rank correlation and the area under the receiver-operating characteristic curve (ROC-AUC).

RESULTS: All tested serum parameters were significantly elevated in patients with progressive disease. The highest sensitivities according to the established thresholds were found for S100ß and MIA (91% and 88%, respectively). LDH had the highest specificity (92%). ESR was dropped from the analysis because of low specificity. In calculating Somers' D_xy and ROC-AUC values, S100ß, MIA, and LDH showed high discrimination ability. By multiple logistic regression, LDH was identified to be the only statistically significant marker for progressive disease. S100ß and MIA did not provide additional significant information because of their high correlation with LDH with respect to clinical outcome.

CONCLUSION: Elevated serum levels of S100ß, MIA, and LDH indicate current disease progression in AJCC stage IV melanoma. LDH was the most relevant overall parameter.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. Helfrich, L. Edler, A. Sucker, M. Thomas, S. Christian, D. Schadendorf, and H. G. Augustin Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma Clin. Cancer Res., February 15, 2009; 15(4): 1384 - 1392. [Abstract] [Full Text] [PDF]

				A. A. Tarhini, J. Stuckert, S. Lee, C. Sander, and J. M. Kirkwood Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694 J. Clin. Oncol., January 1, 2009; 27(1): 38 - 44. [Abstract] [Full Text] [PDF]

				E. L. Korn, P.-Y. Liu, S. J. Lee, J.-A. W. Chapman, D. Niedzwiecki, V. J. Suman, J. Moon, V. K. Sondak, M. B. Atkins, E. A. Eisenhauer, et al. Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials J. Clin. Oncol., February 1, 2008; 26(4): 527 - 534. [Abstract] [Full Text] [PDF]

				H. Schmidt, J. S. Johansen, P. Sjoegren, I. J. Christensen, B. S. Sorensen, K. Fode, J. Larsen, and H. von der Maase Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma J. Clin. Oncol., February 10, 2006; 24(5): 798 - 804. [Abstract] [Full Text] [PDF]

				S. Mian, S. Ugurel, E. Parkinson, I. Schlenzka, I. Dryden, L. Lancashire, G. Ball, C. Creaser, R. Rees, and D. Schadendorf Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients J. Clin. Oncol., August 1, 2005; 23(22): 5088 - 5093. [Abstract] [Full Text] [PDF]

				C. M. Balch, S.-J. Soong, M. B. Atkins, A. C. Buzaid, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr., J. M. Kirkwood, et al. An Evidence-based Staging System for Cutaneous Melanoma CA Cancer J Clin, May 1, 2004; 54(3): 131 - 149. [Abstract] [Full Text] [PDF]

				M. B. Faries, R. K. Gupta, X. Ye, E. C. Hsueh, and D. L. Morton Melanoma-Inhibiting Activity Assay Predicts Survival in Patients Receiving a Therapeutic Cancer Vaccine After Complete Resection of American Joint Committee on Cancer Stage III Melanoma Ann. Surg. Oncol., January 1, 2004; 11(1): 85 - 93. [Abstract] [Full Text] [PDF]

				P. J. Allen and D. G. Coit The Surgical Management of Metastatic Melanoma Ann. Surg. Oncol., October 1, 2002; 9(8): 762 - 770. [Abstract] [Full Text] [PDF]

				C. M. Balch and M. C. Mihm Reply to the article "The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group", by D. J. Ruiter et al. (Ann Oncol 2001; 12: 9-11) Ann. Onc., January 19, 2002; 13(1): 175 - 176. [Full Text] [PDF]

				C. M. Balch, S.-J. Soong, J. E. Gershenwald, J. F. Thompson, D. S. Reintgen, N. Cascinelli, M. Urist, K. M. McMasters, M. I. Ross, J. M. Kirkwood, et al. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System J. Clin. Oncol., August 15, 2001; 19(16): 3622 - 3634. [Abstract] [Full Text] [PDF]

				C. M. Balch, A. C. Buzaid, S.-J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr, J. M. Kirkwood, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma J. Clin. Oncol., August 15, 2001; 19(16): 3635 - 3648. [Abstract] [Full Text] [PDF]

				L. E. Flaherty, M. Atkins, J. Sosman, G. Weiss, J. I. Clark, K. Margolin, J. Dutcher, M. S. Gordon, M. Lotze, J. Mier, et al. Outpatient Biochemotherapy With Interleukin-2 and Interferon Alfa-2b in Patients With Metastatic Malignant Melanoma: Results of Two Phase II Cytokine Working Group Trials J. Clin. Oncol., July 1, 2001; 19(13): 3194 - 3202. [Abstract] [Full Text] [PDF]